专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07807168B2 Selection of human TNFα specific antibodies 失效
标题翻译：人类TNFα特异性抗体的选择
公开(公告)号：US07807168B2
公开(公告)日：2010-10-05
申请号：US12100008
申请日：2008-04-09
申请人： Ernest S. Smith , Leslie A. Croy , Maria G. M. Scrivens
发明人： Ernest S. Smith , Leslie A. Croy , Maria G. M. Scrivens
IPC分类号： A61K39/395
CPC分类号： C07K16/241 , C07K2317/24 , C07K2317/565 , C07K2317/92
摘要： The invention relates to antibodies which bind to tumor necrosis factor α (TNFα) and uses thereof, in particular in the diagnosis and treatment of autoimmune diseases, e.g. rheumatoid arthritis (RA). Specific human monoclonal antibodies which inhibit TNFα-mediated signalling pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human monoclonal antibodies which block the ability of TNFα to bind to its receptor, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating autoimmune diseases, e.g. rheumatoid arthritis (RA), using antibodies of the invention.
摘要翻译：本发明涉及结合肿瘤坏死因子α（TNFα）的抗体及其用途，特别是用于诊断和治疗自身免疫性疾病的抗体。类风湿关节炎（RA）。提供抑制TNFα介导的信号通路的特异性人单克隆抗体及其变体，片段及其衍生物。还提供阻断TNFα与其受体结合的能力的特异性人单克隆抗体，以及这些抗体的片段，变体和衍生物。本发明还包括编码上述抗体或其片段，变体或衍生物的多核苷酸，以及包含这种多核苷酸的载体和宿主细胞。本发明还包括诊断和治疗自身免疫疾病的方法，例如，类风湿性关节炎（RA），使用本发明的抗体。

2. 发明授权

US08834883B2 Anti-VEGF antibodies and uses thereof 有权
标题翻译：抗VEGF抗体及其用途
公开(公告)号：US08834883B2
公开(公告)日：2014-09-16
申请号：US13703947
申请日：2011-06-14
申请人： Leslie A. Croy , Mark J. Paris , Ernest S. Smith
发明人： Leslie A. Croy , Mark J. Paris , Ernest S. Smith
IPC分类号： C07K16/22 , C07K14/475 , G01N33/53 , A61K51/10 , A61K47/48 , A61K39/395
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61N5/10 , C07K2317/24 , C07K2317/76 , C07K2317/92 , G01N33/74 , G01N2333/475
摘要： Provided are monoclonal antibodies and antigen binding fragments thereof that specifically bind vascular endothelial growth factor (VEGF). The anti-VEGF monoclonal antibodies block VEGF binding to its receptors (e.g., VEGFR1 and/or VEGFR2) and prevent phosphorylation of VEGFR2 by VEGF. Also provided are methods of using the monoclonal anti-VEGF antibodies for treatment of disease, including cancer.
摘要翻译：提供特异性结合血管内皮生长因子（VEGF）的单克隆抗体及其抗原结合片段。抗VEGF单克隆抗体阻断VEGF与其受体（例如VEGFR1和/或VEGFR2）结合并阻止VEGF的VEGFR2磷酸化。还提供了使用单克隆抗VEGF抗体治疗疾病（包括癌症）的方法。

3. 发明申请

US20130202615A1 ANTI-VEGF ANTIBODIES AND USES THEREOF 有权
标题翻译：抗VEGF抗体及其用途
公开(公告)号：US20130202615A1
公开(公告)日：2013-08-08
申请号：US13703947
申请日：2011-06-14
申请人： Leslie A. Croy , Mark J. Paris , Ernest S. Smith
发明人： Leslie A. Croy , Mark J. Paris , Ernest S. Smith
IPC分类号： C07K16/22 , A61N5/10 , A61K45/06 , G01N33/74 , A61K47/48 , A61K39/395
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61N5/10 , C07K2317/24 , C07K2317/76 , C07K2317/92 , G01N33/74 , G01N2333/475
摘要： Provided are monoclonal antibodies and antigen binding fragments thereof that specifically bind vascular endothelial growth factor (VEGF). The anti-VEGF monoclonal antibodies block VEGF binding to its receptors (e.g., VEGFR1 and/or VEGFR2) and prevent phosphorylation of VEGFR2 by VEGF. Also provided are methods of using the monoclonal anti-VEGF antibodies for treatment of disease, including cancer.
摘要翻译：提供特异性结合血管内皮生长因子（VEGF）的单克隆抗体及其抗原结合片段。抗VEGF单克隆抗体阻断VEGF与其受体（例如VEGFR1和/或VEGFR2）结合并阻止VEGF的VEGFR2磷酸化。还提供了使用单克隆抗VEGF抗体治疗疾病（包括癌症）的方法。

4. 发明授权

US08741810B2 In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells 有权
标题翻译：在真核细胞中产生和鉴定免疫球蛋白分子的体外方法
公开(公告)号：US08741810B2
公开(公告)日：2014-06-03
申请号：US11892027
申请日：2007-08-17
申请人： Maurice Zauderer , Ernest S. Smith
发明人： Maurice Zauderer , Ernest S. Smith
IPC分类号： C40B10/00
CPC分类号： C07K16/00 , C07K2317/21 , C07K2317/22 , C07K2317/55 , C07K2317/622 , C12N2799/023
摘要： The present invention relates to a high efficiency method of expressing immunoglobulin molecules in eukaryotic cells. The invention is further drawn to a method of producing immunoglobulin heavy and light chain libraries, particularly using the trimolecular recombination method, for expression in eukaryotic cells. The invention further provides methods of selecting and screening for antigen-specific immunoglobulin molecules, and antigen-specific fragments thereof. The invention also provides kits for producing, screening and selecting antigen-specific immunoglobulin molecules. Finally, the invention provides immunoglobulin molecules, and antigen-specific fragments thereof, produced by the methods provided herein.
摘要翻译：本发明涉及在真核细胞中表达免疫球蛋白分子的高效方法。本发明进一步涉及一种生产免疫球蛋白重链和轻链文库的方法，特别是使用三分子重组方法在真核细胞中表达。本发明还提供了选择和筛选抗原特异性免疫球蛋白分子及其抗原特异性片段的方法。本发明还提供用于产生，筛选和选择抗原特异性免疫球蛋白分子的试剂盒。最后，本发明提供了通过本文提供的方法产生的免疫球蛋白分子及其抗原特异性片段。

5. 发明授权

US09382327B2 Anti-CD20 antibodies and methods of use 有权
标题翻译：抗CD20抗体及其使用方法
公开(公告)号：US09382327B2
公开(公告)日：2016-07-05
申请号：US11869170
申请日：2007-10-09
申请人： Ernest S. Smith , Terrence L. Fisher, Jr.
发明人： Ernest S. Smith , Terrence L. Fisher, Jr.
IPC分类号： A61K39/395 , C07K16/30 , C07K16/28 , C12N5/0781 , A61K39/00
CPC分类号： C07K16/2887 , A61K39/39541 , A61K39/39558 , A61K2039/505 , C07K16/3061 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C12N5/0635 , C12N2501/599
摘要： Compositions and methods are provided for treating diseases associated with CD20, including lymphomas, autoimmune diseases, and transplant rejections. Compositions include anti-CD20 antibodies capable of binding to a human CD20 antigen located on the surface of a human CD20-expressing cell, wherein the antibody has increased complement-dependent cell-mediated cytotoxicity (CDC) that is achieved by having at least one optimized CDR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD20 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD20 antibodies.
摘要翻译：提供组合物和方法用于治疗与CD20相关的疾病，包括淋巴瘤，自身免疫疾病和移植排斥。组合物包括能够结合位于人CD20表达细胞表面上的人CD20抗原的抗CD20抗体，其中所述抗体具有增加的补体依赖性细胞介导的细胞毒性（CDC），其通过使至少一种优化的 CDR在抗体的可变区内工程化。组合物还包括单克隆抗体的抗原结合片段，变体和衍生物，产生这些抗体组合物的细胞系和编码抗体氨基酸序列的分离的核酸分子。本发明还包括药物组合物，其包含本发明的抗CD20抗体或其药学上可接受的载体中的抗原结合片段，变体或衍生物，以及这些抗CD20抗体的使用方法。

6. 发明授权

US08816058B2 Polynucleotides encoding anti-CD100 antibodies or antigen-binding fragments thereof 有权
标题翻译：编码抗CD100抗体的多核苷酸或其抗原结合片段
公开(公告)号：US08816058B2
公开(公告)日：2014-08-26
申请号：US13517807
申请日：2012-06-14
申请人： Ernest S. Smith , Terrence Lee Fisher
发明人： Ernest S. Smith , Terrence Lee Fisher
IPC分类号： C07H21/04 , C12N1/20
CPC分类号： C07K16/2803 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K16/2896 , C07K16/30 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： Isolated polynucleotides are provided which encode antibody VH and VL polypeptides, and anti-CD100 antibodies and antigen-binding fragments thereof. In another aspect, the invention provides a vector comprising a polynucleotide of the invention. In another aspect, the invention provides a host cell comprising the vector of the invention. In another aspect, the invention provides a method of producing an antibody of the invention, e.g., for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers.
摘要翻译：提供了分离的多核苷酸，其编码抗体VH和VL多肽，以及编码抗CD100抗体及其抗原结合片段。另一方面，本发明提供了包含本发明多核苷酸的载体。另一方面，本发明提供了包含本发明载体的宿主细胞。另一方面，本发明提供了制备本发明抗体的方法，例如用于治疗与CD100相关的疾病，包括某些自身免疫疾病，炎性疾病和癌症。

7. 发明授权

US08496938B2 Anti-CD100 neutralizing neutralizing antibodies and methods of using the same 有权
标题翻译：抗CD100中和抗体及其使用方法
公开(公告)号：US08496938B2
公开(公告)日：2013-07-30
申请号：US12776187
申请日：2010-05-07
申请人： Ernest S. Smith , Terrence Lee Fisher
发明人： Ernest S. Smith , Terrence Lee Fisher
IPC分类号： A61K39/395 , A61K39/00
CPC分类号： C07K16/2803 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K16/2896 , C07K16/30 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.
摘要翻译：提供组合物和方法用于治疗与CD100相关的疾病，包括某些自身免疫疾病，炎性疾病和癌症。特别地，已经开发了抗CD100单克隆抗体来中和CD100。

8. 发明申请

US20090081210A1 Methods of Killing Tumor Cells by Targeting Internal Antigens Exposed on Apoptotic Tumor Cells 审中-公开
标题翻译：通过靶向暴露于凋亡性肿瘤细胞的内部抗原杀死肿瘤细胞的方法
公开(公告)号：US20090081210A1
公开(公告)日：2009-03-26
申请号：US12125849
申请日：2008-05-22
申请人： Elizabeth E. Evans , Mark J. Paris , Deepak M. Sahasrabudhe , Maurice Zauderer , Ernest S. Smith
发明人： Elizabeth E. Evans , Mark J. Paris , Deepak M. Sahasrabudhe , Maurice Zauderer , Ernest S. Smith
IPC分类号： A61K39/395 , C07K16/18 , C12N15/11 , C12N15/00 , C12N5/06
CPC分类号： C07K16/30 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/73
摘要： The invention provides in vitro and in vivo methods of killing cancer cells, including therapeutic methods in humans, and also provides antibodies specific for the cancer specific antigen C35, and polynucleotides encoding such antibodies, as well as therapeutic and diagnostic methods of using such antibodies.
摘要翻译：本发明提供了杀死癌细胞的体外和体内方法，包括在人体中的治疗方法，并且还提供对癌症特异性抗原C35特异性的抗体，以及编码这种抗体的多核苷酸以及使用这种抗体的治疗和诊断方法。

9. 发明申请

US20080305111A1 Anti-C35 antibodies for treating cancer 审中-公开
标题翻译：抗C35抗体治疗癌症
公开(公告)号：US20080305111A1
公开(公告)日：2008-12-11
申请号：US11812996
申请日：2007-06-22
申请人： Elizabeth E. Evans , Mark J. Paris , Deepak M. Sahasrabudhe , Maurice Zauderer , Ernest S. Smith
发明人： Elizabeth E. Evans , Mark J. Paris , Deepak M. Sahasrabudhe , Maurice Zauderer , Ernest S. Smith
IPC分类号： A61K39/395 , C12N5/00 , C07K16/00 , C07H21/00 , C12N15/63 , C12P21/00 , G01N33/53 , A61P35/00
CPC分类号： C07K16/30 , A61K39/39558 , A61K45/06 , A61K2039/507 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/92 , A61K2300/00
摘要： The present invention is directed to methods of killing cancer cells, the methods comprising administering at least one C35 antibody and a chemotherapeutic agent. In some preferred embodiments, two C35 antibodies are administered with a chemotherapeutic agent. The present invention is further directed to C35 antibodies useful in these methods.
摘要翻译：本发明涉及杀死癌细胞的方法，所述方法包括施用至少一种C35抗体和化学治疗剂。在一些优选的实施方案中，两种C35抗体与化学治疗剂一起施用。本发明还涉及可用于这些方法的C35抗体。

10. 发明申请

US20150050287A9 ANTI-CXCL13 ANTIBODIES AND METHODS OF USING THE SAME 有权
标题翻译：抗CXCL13抗体及其使用方法
公开(公告)号：US20150050287A9
公开(公告)日：2015-02-19
申请号：US13820278
申请日：2011-09-01
申请人： Ekaterina Klimatcheva , Mark Paris , Ernest S. Smith
发明人： Ekaterina Klimatcheva , Mark Paris , Ernest S. Smith
IPC分类号： C07K16/24
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/73 , C07K2317/92
摘要： Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.
摘要翻译：提供组合物和方法用于治疗与CXCL13表达相关的疾病，包括某些自身免疫性疾病，炎性疾病和癌症。特别地，已经开发了抗CXCL13单克隆抗体来中和CXCL13。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式